SAN DIEGO–(BUSINESS WIRE)–Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused
on discovering, acquiring, developing and commercializing therapeutics
in the disease areas of immunology, inflammation and oncology, today
announced that it has filed an amended registration statement on Form
S-1 with the U.S. Securities and Exchange Commission (the “SEC”) in
connection with its proposed initial public offering of its common
stock. The amended registration statement restores the delaying
amendment language contemplated by Rule 473(a) promulgated under the
Securities Act of 1933, as amended (the “Securities Act”), such that the
registration statement Gossamer Bio filed on January 23, 2019 will no
longer become automatically effective pursuant to Section 8(a) of the
Securities Act 20 calendar days after its filing date. With today’s
filing, Gossamer Bio intends to request from the SEC acceleration of the
effective date of the registration statement prior to the date that it
would have otherwise become automatically effective.
Gossamer Bio previously announced that it had filed a registration
statement on January 23, 2019 offering 14,375,000 shares of its common
stock at an initial public offering price of $16.00 per share. The
proposed offering terms have not changed. Gossamer Bio’s common stock
has been approved for listing on the Nasdaq Global Select Market under
the symbol “GOSS.” Gossamer Bio expects to grant the underwriters a
30-day option to purchase up to an additional 2,156,250 shares of common
stock in connection with the offering. All of the shares are being sold
by Gossamer Bio.
BofA Merrill Lynch, SVB Leerink, Barclays and Evercore ISI are acting as
joint book-running managers for the proposed offering.
A registration statement relating to these securities has been filed
with the SEC, but has not yet become effective. These securities may not
be sold, nor may offers to buy be accepted, prior to the time the
registration statement becomes effective. This press release shall not
constitute an offer to sell or a solicitation of an offer to buy, nor
shall there be any offer or sale of, these securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of such
state or jurisdiction.
The proposed offering will be made only by means of a prospectus. Copies
of the preliminary prospectus relating to the proposed offering may be
obtained, when available, from: BofA Merrill Lynch, NC1-004-03-43, 200
North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention:
Prospectus Department, or by email at dg.prospectus_requests@baml.com;
or from SVB Leerink, Attention: Syndicate Department, One Federal
Street, 37th Floor, Boston, MA 02110, or by email at syndicate@leerink.com,
or by telephone at (800) 808-7525, ext. 6132; or from Barclays, c/o
Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long
Island Avenue, Edgewood, NY 11717, or by telephone at (888) 603-5847, or
by email at Barclaysprospectus@broadridge.com;
or from Evercore ISI, Attention: Equity Capital Markets, 55 East 52nd
Street, 36th Floor, New York, NY 10055, or by telephone at (888)
474-0200, or by email at ecm.prospectus@evercore.com.
Contacts
Gossamer Bio:
For Investors:
Argot Partners
Kimberly
Minarovich
Tel 212.600.1902
kimberly@argotpartners.com
For Media:
Argot Partners
David Rosen
Tel 212.600.1902
david.rosen@argotpartners.com
